Detalhe da pesquisa
1.
Real-world effectiveness of the heterologous SOBERANA-02 and SOBERANA-Plus vaccine scheme in 2-11 years-old children during the SARS-CoV-2 Omicron wave in Cuba: a longitudinal case-population study.
Lancet Reg Health Am
; 34: 100750, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38699214
2.
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial.
Lancet Reg Health Am
; 18: 100423, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36618081
3.
Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children.
Int J Infect Dis
; 126: 164-173, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36403819
4.
Repeat-dose and local tolerance toxicity of SARS-CoV-2 FINLAY-FR-02 vaccine candidate in Sprague Dawley rats.
Toxicology
; 471: 153161, 2022 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35364223
5.
Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults.
Med
; 3(11): 760-773.e5, 2022 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35998623
6.
Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials.
Vaccine
; 40(31): 4220-4230, 2022 07 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35691871
7.
OMV-based vaccine formulations against Shiga toxin producing Escherichia coli strains are both protective in mice and immunogenic in calves.
Hum Vaccin Immunother
; 14(9): 2208-2213, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29923791
8.
Reactividad de sueros de ratones inmunizados con vesículas de membrana externa derivadas de Salmonella entérica / Reactivity of sera from mice immunized with outer membrane vesicles derived from Salmonella enterica
Vaccimonitor (La Habana, Print)
; 30(1)ene.-abr. 2021. graf
Artigo
em Espanhol
| CUMED, LILACS | ID: biblio-1150250
9.
Condiciones de adsorción de un candidato vacunal basado en vesículas de membrana externa derivada de Salmonella Paratyphi A en adyuvantes de aluminio / Adsorption conditions of a vacunal candidate based on outer membrane vesicles of Salmonella Paratyphi A in aluminum adjuvants
Vaccimonitor (La Habana, Print)
; 28(2)mayo.-ago. 2019. tab, graf
Artigo
em Espanhol
| LILACS, CUMED | ID: biblio-1094625
10.
Estandarización de un ELISA para la cuantificación de anticuerpos IgG contra vesículas de membrana externa de Salmonella Paratyphi A / Standardization of an ELISA for the quantification of IgG antibodies against outer membrane vesicle of Salmonella Paratyphi A
Vaccimonitor (La Habana, Print)
; 27(3)set.-dic. 2018. ilus, tab
Artigo
em Espanhol
| LILACS, CUMED | ID: biblio-1094610
11.
Antigenicidad e inmunogenicidad de una cepa inactivada de Vibrio cholerae O1 El Tor Inaba / Antigenicity and immunogenicity of inactivated Vibrio cholerae 01 El Tor Inaba
Rev. cuba. med. trop
; 61(3): 275-281, sep.-dic. 2009.
Artigo
em Espanhol
| LILACS | ID: lil-629367